Project title: Drug discovery and design for the $\alpha_1$-adrenoceptors

Supervisor names: Dr Alaa Abdul-Ridha (main) and Dr Daniel Scott

Contact Email: alaa.abdul@florey.edu.au

Location of work: The Florey Institute of Neuroscience and Mental Health, Kenneth Myer Building.

Honours project available for ONE student

The $\alpha_{1A}$- and $\alpha_{1B}$-adrenoceptors ($\alpha_{1A}$-AR and $\alpha_{1B}$-AR) are closely related G protein-coupled receptors (GPCRs) that modulate the peripheral and central nervous systems in response to binding adrenaline and noradrenaline. While these receptors are known for their regulation of vascular tone and are targeted clinically to treat hypertension and BPH, the role of individual sub-types is unknown in the CNS and the periphery due to a lack of subtype-selective ligands. The $\alpha_{1A}$-AR and $\alpha_{1B}$-AR are putative drug targets for treating numerous diseases including depression, heart failure, epilepsy and Alzheimer’s disease but their role as clinical targets for these diseases needs to be validated with subtype-selective tool ligands. Fragment screening is an approach for identifying and optimizing compounds for various protein targets but has been generally difficult to apply to GPCRs due to the instability of purified receptor preparations needed for biophysical screening methods. Our laboratory generated thermostabilized $\alpha_{1A}$-AR and $\alpha_{1B}$-AR variants suitable for biophysical studies, allowing the screening of a small, yet diverse fragment library with NMR spectroscopy and surface plasmon resonance. This screen identified two hits, the first of which exhibits a 10-fold selectivity for inhibiting $\alpha_{1B}$-AR signalling and the second hit was a selective $\alpha_{1A}$-AR agonist which also displayed a negative allosteric mode of action at the $\alpha_{1B}$-AR. This project aims to understand the structural basis of binding and selectivity of these hits and understand the structure-activity relationships (SAR) of the hit molecules at each receptor. This will be probed using traditional molecular pharmacology techniques involving binding assays and measuring receptor activation using multiple signalling outputs on WT and mutant receptors. Computational ligand docking and ligand design will also be applied to guide SAR studies. The resultant information will be used to develop novel compounds to elucidate the individual physiological roles of $\alpha_{1A}$-AR and $\alpha_{1B}$-AR and their potential as targets for disease treatments. Students will be trained in: molecular cloning techniques, GPCR pharmacological assays including ligand binding and cell signalling assays, computational ligand docking and ligand design.